Document Library
Filter by country
Africa
Angola
Benin
Burkina Faso
Burundi
Cameroon
Central African Republic (the)
Chad
Comoros (the)
Congo (the)
Cote d'Ivoire
Congo, DR
Eritrea
Ethiopia
The Gambia
Ghana
Guinea-Bissau
Guinea
Kenya
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mozambique
Niger
Nigeria
Rwanda
Sao Tome and Principe
Senegal
Sierra Leone
South Sudan
Tanzania, UR
Togo
Uganda
Zambia
Zimbabwe
South-East Asia
Bangladesh
Bhutan
Korea, DPR
India
Myanmar
Nepal
Sri Lanka
Timor Leste
Americas
Cuba
Haiti
Honduras
Nicaragua
Bolivia
Guyana
Europe
Albania
Armenia
Azerbaijan
Bosnia-Herzegovina
Georgia
Kyrgyzstan
Moldova
Tajikistan
Turkmenistan
Ukraine
Uzbekistan
Western Pacific
Cambodia
China
Indonesia
Kiribati
Lao PDR
Mongolia
Papua New Guinea
Solomon Islands
Vietnam
Eastern Mediterranean
Afghanistan
Djibouti
Pakistan
Somalia
Sudan (the)
Yemen
Filter by type
Country
Africa
South-East Asia
Americas
Europe
Western Pacific
Eastern Mediterranean
Documents
Annual Reports
AMC Documents
Country Documents
Evaluations
Financial Reports
Guidelines and Forms
Legal
Strategy
Supply and Procurement
Policies
White papers
Gavi Fact Sheets
Gavi Publications
The Evidence Base
Gavi Bulletin
Other Publishers
Board Minutes
Committee minutes
Audit
Spanish
Russian
IRC reports
Portuguese
Annual Contributions and Proceeds
Cash Receipts
Advocacy
Resource mobilisation
German
COVID-19 situation report
COVAX documents
COVAX AMC
Gavi Process Guidelines
Gavi Programme Funding Guidelines
Programme audit
Internal audit
Investigation
Reports to the Board
Other (IA)
COVAX data brief
DHI
VIS
News
AMC Updates
Gavi Features
Press Releases
Roi
Statements
Gavi Blogs
Vaccineswork
Theme - Pentavalent
Top stories
3rd donor pledging
3rd donor pledging featured
Partner news
IATI
Social media toolkit
Audio Visual
Infographics
Presentations
Videos
Galleries
Market shaping
Phase I - innovations
Phase II - innovations
VIPS
Gender
Board
Committee
Members
Donor
Japan
Governments EU
Foundations corps orgs
RFP
Country managed evaluations
Old RFP
Centralised evaluations (EAC)
3rd donor pledging announcements
Types of support
Human papillomavirus
Inactivated polio vaccine
Japanese encephalitis
Measles and measles-rubella
Meningitis A
Oral cholera
Pentavalent
Pneumococcal
Rotavirus
Typhoid
Yellow fever
Health system strengthening
Hexavalent
DTP-containing booster
Board meetings
COVAX roll-out
Africa COVAX roll-out
Americas COVAX roll-out
Eastern Mediterranean COVAX roll-out
Europe COVAX roll-out
SE Asia COVAX roll-out
Western Pacific COVAX roll-out
Decentralised Evaluations
Decentralised Evaluations pages
Knowledge Products
Discussion Paper
Annual Evaluation Reports
Other learning products
CSO
CSO news
CSO story
CSO learning brief
Africa
Angola
Benin
Burkina Faso
Burundi
Cameroon
Central African Republic (the)
Chad
Comoros (the)
Congo (the)
Cote d'Ivoire
Congo, DR
Eritrea
Ethiopia
The Gambia
Ghana
Guinea-Bissau
Guinea
Kenya
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mozambique
Niger
Nigeria
Rwanda
Sao Tome and Principe
Senegal
Sierra Leone
South Sudan
Tanzania, UR
Togo
Uganda
Zambia
Zimbabwe
South-East Asia
Bangladesh
Bhutan
Korea, DPR
India
Myanmar
Nepal
Sri Lanka
Timor Leste
Americas
Cuba
Haiti
Honduras
Nicaragua
Bolivia
Guyana
Europe
Albania
Armenia
Azerbaijan
Bosnia-Herzegovina
Georgia
Kyrgyzstan
Moldova
Tajikistan
Turkmenistan
Ukraine
Uzbekistan
Western Pacific
Cambodia
China
Indonesia
Kiribati
Lao PDR
Mongolia
Papua New Guinea
Solomon Islands
Vietnam
Eastern Mediterranean
Afghanistan
Djibouti
Pakistan
Somalia
Sudan (the)
Yemen
Annual Reports
AMC Documents
Manufacturers related
Strategic Demand Forecast
Target Product Profile
Legal Agreements
Remaining offer amount
Country Documents
Approved proposals
Comprehensive multi-year plans, Financial sustainability plans, National Immunisation Strategy
Country co-financing information sheet
Data quality audit
Decision Letters and Partnerships Agreement
The joint appraisal report and Multi-Stakeholder Dialogue
Targeted country assistance plans
HSS evaluation
HSS tracking study
Annual progress reports
COVAX Technical Assistance Plans
Evaluations
CSO 2012
Full country evaluations
Second evaluation
IFFIm evaluation
HSS evaluation
TCA
Other studies
CSO 2018
Financial Reports
Guidelines and Forms
General
Japanese encephalitis vaccine
Meningitis A vaccine
Pneumococcal vaccine
Rotavirus vaccine
Typhoid vaccine
Yellow fever vaccine
HSS support
CCEOP support
Report on and renew support
TCA
Additional guidance
Joint appraisals
Tools and templates
Legal
Strategy
Phase 4
Phase 5
Phase 3
Phase 2
Phase 1
Risk
Supply and Procurement
Roadmaps
Base demand forecast
Detailed product profiles
Strategy 2016-20
Policies
Corporate
Programmatic
White papers
Gavi Fact Sheets
Gavi Publications
Japanese
Gavi progress reports
Arabic
Investment opportunity
The Evidence Base
Gavi Bulletin
Other Publishers
Board Minutes
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Decisions
Programme
2020
2021
2022
2023
2024
2025
2026
Committee minutes
PPC
EAC
IC
AFC
GC
Audit
Spanish
Russian
IRC reports
Portuguese
Annual Contributions and Proceeds
Cash Receipts
Advocacy
Resource mobilisation
German
COVID-19 situation report
COVAX documents
COVAX AMC
COVAX AMC VR
COVAX AMC TA
COVAX AMC CCE
COVAX AMC CDS (EA)
COVAX AMC CDS (NB)
Legal 1
Legal 2
Gavi Process Guidelines
Human papillomavirus vaccine
Measles and measles-rubella vaccines
Application Process
Application Kit
Analysis
Vaccine Information & Switches
Ongoing Portfolio Management, Reporting & Renewals
Financial Management & Reporting
Joint-Appraisal & Multi Stakeholder Dialogue
IPV
Meningococcal vaccines
Pneumococcal vaccine
Rotavirus vaccine
Typhoid vaccine
Yellow fever vaccine
Malaria vaccine
Cholera vaccine (OCV)
Gavi process guidelines 5.0
Vaccine switch information
Hexavalent guidelines
Ebola
Human rabies vaccine for post-exposure prophylasis
DTP guidelines
Gavi process guidelines 6.0
Gavi Programme Funding Guidelines
Zero-dose
Maintain, Restore & Strengthen
Demand, Communities and Gender
Supply Chain & Cold Chain Equipment
Data
Leadership, Management and Coordination
Immunisation Financing
Gavi Programme Funding Guidelines – Main
Additional Resources
Programme audit
Internal audit
Investigation
Reports to the Board
Other (IA)
COVAX data brief
DHI
Case studies & technical briefs
Practical guides
Digital Health Information Strategy
Research publications
VIS
VIS 2018
AMC Updates
Gavi Features
Press Releases
COVAX latest
Gavi partner
Roi
Statements
Gavi Blogs
Vaccineswork
Primary health care
Universal health care
Equity
Gender
Outbreaks
Technology and innovation
Antimicrobial resistance
Climate change
Urbanisation
Identity
Opinions
Country stories
COVID-19
Most read
Review
Partner
Featured VW articles
Featured Large VW article
MTR
Theme - Pentavalent
Top stories
HEHR
3rd donor pledging
Alliance partners
3rd donor pledging featured
Partner news
IATI
Social media toolkit
Angola
Benin
Burkina Faso
Burundi
Cameroon
Central African Republic (the)
Chad
Comoros (the)
Congo (the)
Cote d'Ivoire
Congo, DR
Eritrea
Ethiopia
The Gambia
Ghana
Guinea-Bissau
Guinea
Kenya
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mozambique
Niger
Nigeria
Rwanda
Sao Tome and Principe
Senegal
Sierra Leone
South Sudan
Tanzania, UR
Togo
Uganda
Zambia
Zimbabwe
Manufacturers related
Strategic Demand Forecast
Target Product Profile
Legal Agreements
Remaining offer amount
Approved proposals
Approved proposals
Comprehensive multi-year plans, Financial sustainability plans, National Immunisation Strategy
Comprehensive multi-year plans, Financial sustainability plans, National Immunisation Strategy
Country co-financing information sheet
Country co-financing information sheet
Data quality audit
Data quality audit
Decision Letters and Partnerships Agreement
Decision Letters and Partnerships Agreement
The joint appraisal report and Multi-Stakeholder Dialogue
The joint appraisal report and Multi-Stakeholder Dialogue
Targeted country assistance plans
Targeted country assistance plans
HSS evaluation
HSS evaluation
HSS tracking study
HSS tracking study
Annual progress reports
Annual progress reports
COVAX Technical Assistance Plans
COVAX Technical Assistance Plans
CSO 2012
Full country evaluations
FCE 2016
FCE 2015
FCE 2014
FCE 2013
Second evaluation
IFFIm evaluation
HSS evaluation
Gavi managed evaluations
Summaries
TCA
Other studies
CSO 2018
General
Japanese encephalitis vaccine
Meningitis A vaccine
Pneumococcal vaccine
Rotavirus vaccine
Typhoid vaccine
Yellow fever vaccine
HSS support
CCEOP support
Report on and renew support
Tools and templates
Additional info
TCA
Additional guidance
Financial management
Programming guidance
Requirements for implementation
Gender related barriers
Immunisation financing
Leadership management coordination
Improving data quality
Joint appraisals
Tools and templates
Phase 4
Phase 5
Phase 3
Phase 2
Phase 1
Risk
Roadmaps
Vaccine roadmap
CCE roadmap
Diagnostics roadmaps
Base demand forecast
Detailed product profiles
Strategy 2016-20
COVAX latest
Gavi partner
Corporate
Programmatic
Infographics
Presentations
Videos
Galleries
Japanese
Gavi progress reports
Arabic
Investment opportunity
Primary health care
Universal health care
Equity
Gender
Outbreaks
Technology and innovation
Antimicrobial resistance
Climate change
Urbanisation
Identity
Opinions
Seth Berkley
Ngozi Okonjo-Iweala
Anuradha Gupta
Sania Nishtar
Country stories
COVID-19
Explainer
Blog
Key news
COVAX
COVAX AMC articles
Most read
1 Trending
2 Trending
3 Trending
4 Trending
5 Trending
6 Trending
Review
Partner
Featured VW articles
Featured Large VW article
MTR
Phase I - innovations
Phase II - innovations
VIPS
Vaccine roadmap
CCE roadmap
Diagnostics roadmaps
Bangladesh
Bhutan
Korea, DPR
India
Myanmar
Nepal
Sri Lanka
Timor Leste
Cuba
Haiti
Honduras
Nicaragua
Bolivia
Guyana
Albania
Armenia
Azerbaijan
Bosnia-Herzegovina
Georgia
Kyrgyzstan
Moldova
Tajikistan
Turkmenistan
Ukraine
Uzbekistan
Cambodia
China
Indonesia
Kiribati
Lao PDR
Mongolia
Papua New Guinea
Solomon Islands
Vietnam
2019
26 June
26 June Presentations
4 Dec
4 Dec presentations
2018
6 June
28 Nov OLD
6 June presentations
28 Nov presentations
28 Nov
28 Nov Pre-Board briefings
6 June pre-board briefings
28 Nov NEW
2017
14 June
7 July
29 Nov
14 June presentations
29 Nov presentations
29 Nov NEW
14 June Tech briefings
14 June NEW
2016
22 June
7 Dec
22 June presentations
7 Dec presentations
22 June Tech briefings
2015
10 June
2 Dec
10 June presentations
2 Dec presentations
2 Dec Tech briefings
10 June Tech briefings
2014
18 June
10 Dec
18 June presentations
10 Dec presentations
10 Dec Tech briefings
18 June Tech briefings
2013
11 June
21 Nov
11 June presentations
21 Nov presentations
2012
12 June
4 Dec
12 June presentations
4 Dec presentations
2011
7 July
16 Nov
7 July presentations
16 Nov presentations
2010
16 June
30 Nov
16 June presentations
30 Nov presentations
2009
Decisions
Programme
Governance
Investment
Audit
Evaluation
2020
19 March
11 May
24 June
24 June presentations
30 July
30 July Presentations
29 Sept
29 Sept Presentations
15-17 Dec
15-17 Dec Presentations
2021
22 March
22 March Presentations
23-24 June
23-24 June Presentations
28 Sept
28 Sept Presentations
30 Nov - 2 Dec
30 Nov - 2 Dec Presentations
Board Decision
2022
22-23 June
22-23 June Presentations
7-8 December
7-8 December Presentations
Board Decision
2023
Board Decision
26-27 June
26-27 June Presentations
6-7 December
6-7 December Presentations
2024
6-7 June
6-7 June Presentations
Board Decision
4-5 December
4-5 December Presentations
2025
24-25 July
24-25 July Presentations
Board Decision
3-4 December
3-4 December Presentations
2026
1-2 July
1-2 July Presentations
Board Decision
26 June
26 June Presentations
4 Dec
4 Dec presentations
6 June
28 Nov OLD
6 June presentations
28 Nov presentations
28 Nov
28 Nov Pre-Board briefings
6 June pre-board briefings
28 Nov NEW
14 June
7 July
29 Nov
14 June presentations
29 Nov presentations
29 Nov NEW
14 June Tech briefings
14 June NEW
22 June
7 Dec
22 June presentations
7 Dec presentations
22 June Tech briefings
10 June
2 Dec
10 June presentations
2 Dec presentations
2 Dec Tech briefings
10 June Tech briefings
18 June
10 Dec
18 June presentations
10 Dec presentations
10 Dec Tech briefings
18 June Tech briefings
11 June
21 Nov
11 June presentations
21 Nov presentations
12 June
4 Dec
12 June presentations
4 Dec presentations
7 July
16 Nov
7 July presentations
16 Nov presentations
16 June
30 Nov
16 June presentations
30 Nov presentations
PPC
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2020
2021
2022
2023
2024
2025
2026
EAC
2009
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2020
2021
2022
2023
2024
2025
IC
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2020
2021
2022
2023
2024
2026
AFC
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2020
2021
2022
2023
2024
2025
2026
GC
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2020
2021
2022
2023
2024
2025
2026
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2020
2021
2022
2023
2024
2025
2026
2009
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2020
2021
2022
2023
2024
2025
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2020
2021
2022
2023
2024
2026
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2020
2021
2022
2023
2024
2025
2026
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2020
2021
Recommendation
2022
Recommendation
2023
Recommendation
2024
Recommendation
2025
2026
Recommendation
Seth Berkley
Ngozi Okonjo-Iweala
Anuradha Gupta
Sania Nishtar
Committee
Members
Japan
Governments EU
Foundations corps orgs
Tools and templates
Additional info
Financial management
Programming guidance
Requirements for implementation
Gender related barriers
Immunisation financing
Leadership management coordination
Improving data quality
Governance
Investment
Audit
Evaluation
Afghanistan
Djibouti
Pakistan
Somalia
Sudan (the)
Yemen
FCE 2016
FCE 2015
FCE 2014
FCE 2013
Gavi managed evaluations
Summaries
HEHR
Alliance partners
Explainer
Blog
Key news
COVAX
COVAX key articles
COVAX AMC articles
Human papillomavirus
Inactivated polio vaccine
Japanese encephalitis
Measles and measles-rubella
Meningitis A
Oral cholera
Pentavalent
Pneumococcal
Rotavirus
Typhoid
Yellow fever
Health system strengthening
Hexavalent
DTP-containing booster
19 March
11 May
24 June
24 June presentations
30 July
30 July Presentations
29 Sept
29 Sept Presentations
15-17 Dec
15-17 Dec Presentations
1 Trending
2 Trending
3 Trending
4 Trending
5 Trending
6 Trending
COVAX key articles
COVAX AMC VR
COVAX AMC TA
COVAX AMC CCE
COVAX AMC CDS (EA)
COVAX AMC CDS (NB)
Legal 1
Legal 2
Africa COVAX roll-out
Americas COVAX roll-out
Eastern Mediterranean COVAX roll-out
Europe COVAX roll-out
SE Asia COVAX roll-out
Western Pacific COVAX roll-out
22 March
22 March Presentations
23-24 June
23-24 June Presentations
28 Sept
28 Sept Presentations
30 Nov - 2 Dec
30 Nov - 2 Dec Presentations
Board Decision
Recommendation
Human papillomavirus vaccine
Measles and measles-rubella vaccines
Application Process
Application Kit
FPP Application Guidelines & Materials
Standalone EAF Application Materials & Guidelines
Standalone Vaccine Application Materials & Guidelines
Standalone TCA Application Materials & Guidelines
Standalone CCEOP Application Materials & Guidelines
Standalone Innovation Top-up Application Materials & Guidelines
Gavi Middle Income Countries (MICs)
Analysis
Vaccine Information & Switches
Ongoing Portfolio Management, Reporting & Renewals
Financial Management & Reporting
Joint-Appraisal & Multi Stakeholder Dialogue
IPV
Meningococcal vaccines
Pneumococcal vaccine
Rotavirus vaccine
Typhoid vaccine
Yellow fever vaccine
Malaria vaccine
Cholera vaccine (OCV)
Gavi process guidelines 5.0
Vaccine switch information
Hexavalent guidelines
Ebola
Human rabies vaccine for post-exposure prophylasis
DTP guidelines
Gavi process guidelines 6.0
Gavi 6.0 application kit
FPP Application Guidelines & Materials
Standalone EAF Application Materials & Guidelines
Standalone Vaccine Application Materials & Guidelines
Standalone TCA Application Materials & Guidelines
Standalone CCEOP Application Materials & Guidelines
Standalone Innovation Top-up Application Materials & Guidelines
Gavi Middle Income Countries (MICs)
Zero-dose
Maintain, Restore & Strengthen
Demand, Communities and Gender
Supply Chain & Cold Chain Equipment
Data
Leadership, Management and Coordination
Immunisation Financing
Gavi Programme Funding Guidelines – Main
Additional Resources
Discussion Paper
22-23 June
22-23 June Presentations
7-8 December
7-8 December Presentations
Board Decision
Recommendation
Board Decision
26-27 June
26-27 June Presentations
6-7 December
6-7 December Presentations
Recommendation
Case studies & technical briefs
Practical guides
Digital Health Information Strategy
Research publications
VIS 2018
6-7 June
6-7 June Presentations
Board Decision
4-5 December
4-5 December Presentations
Recommendation
CSO news
CSO story
CSO learning brief
24-25 July
24-25 July Presentations
Board Decision
3-4 December
3-4 December Presentations
Gavi 6.0 application kit
1-2 July
1-2 July Presentations
Board Decision
Recommendation
06a Amendment and utilisation of the European Investment Bank EIB Frontloading Facility pdf
Board- 2026-Mtg- 02-Doc 06a 1
Report to the Board
1 -2 July 2026
Subject Amendment and utilisation of the European Investment Bank
(EIB) Frontloading Facility
Agenda item 06 a
Category For Decision
Executive Summary
The purpose of this paper is to request that the Gavi Board ratify the amendment to
the European Investment Bank (EIB) Frontloading Facility executed in December
2025 and approve the potential utilisation of up to EUR 500 million under the Facility.
The Facility is a core pillar of Gavi’s innovative finance toolkit, enabling the Alliance
to convert donor commitments into immediate impact and protecting programme
delivery in a period of heightened fiscal uncertainty . Building on a strong track
record, including a EUR 600 million facility deployed in 2022 and repaid, the
instrument provides predictable, just‑in ‑ time liquidity to support market shaping,
safeguard core programmes, and ensure rapid response capacity for health
emergencies. The December 2025 amendment extends the availability of the
Facility through 2026 with limited technical changes, preserving acc ess to this
proven financing tool at a critical time. The proposed drawdown authorisation of up
to EUR 500 mil lion provides flexibility to respond to evolving liquidity needs, with
utilisation phased based on operational requirements. These proposals were
reviewed by the Audit and Finance Committee at its May 2026 meeting, which
recommended approval to the Board.
Action Requested of the Board
The Gavi Alliance Audit and Finance Committee recommends to the Gavi Alliance
Board that it:
a) Approve the ratification of the amendment to the European Investment Bank
(EIB) Frontloading Facility executed by the Chief Executive Officer in December
2025 as set out in Annex B to Doc 06a ; and
b) Approve the utilisation of the EIB Frontloading Facility through drawdowns of up
to EUR 500 million, subject to satisfaction of all conditions precedent.
Next steps/timeline
Subject to Board approval and satisfaction of all conditions precedent, the
Secretariat will operationalise the Facility and execute drawdowns as required
based on liquidity needs.
06a Annex A Implications and anticipated impacts pdf
Board- 2026-Mtg- 02-Doc 06a-Annex A 1
Report to the Board
1 -2 July 2026
Annex A: Implications and anticipated impact s
• Risk implication and mitigation, including information on the risks of inaction
- The extension of EIB’s Facility provides Gavi with a critical fundraising and
liquidity management tool.
- Absent this extended Facility , Gavi risks not being prepared to adapt to donor
budgetary constraints or having necessary liquidity to respond to emerging
needs in 2026 .
- As the Facility is the only frontloading facility for direct grants currently available,
without the amendment Gavi risk s being unprepared to respond to the evolution
of financing needs.
- As the amendment is focused on select key terms, the Secretariat’s
assessment is that the amendment does not increase any risks compared to
prior EIB frontloading agreements .
- The use of EIB funds requires robust functions to operationalise the facility,
absent which Gavi could be subject to operational risks .
- The Facility is intended to be leveraged for Gavi’s needs as well as serve as an
important source of surge liquidity; should utilisation not materialise there could
be risks to Gavi’s reputation with financing partners or donors related to the
value or eff ectiveness of financing instruments .
• Impact on countries
- N/A
• Impact on Alliance
- N/A
• Legal and governance implications
- In accordance with Gavi’s Delegation of Authority Policy, financing
arrangements under which Gavi assumes liabilities in excess of US$ 50 million
requires prior recommendation by the Audit and Finance Committee and
approval by the Board. The current approval would serve as the necessary
approval for the Secretariat to undertake one or more drawdowns of the Facility
up to EUR 500 million in aggregate.
06a Annex B Summary of key terms pdf
Board- 2026-Mtg- 02-Doc 06a-Annex B 1
Report to the Board
1 -2 July 2026
Annex B: Summary of key terms
Term Details
Facility Size EUR 1,000,000,000
Drawdown Period 12 months from Amendment Deed (extended 1 year through 2026)
Tranche Size Min. EUR 40m, up to 10 tranches per credit
Tranche Maturity 18 months to 6 years from disbursement (prepayable if needed)
Interest Rate
Floating EURIBOR for EUR drawdown + spread (spread set at time of
EIB offer per tranche)
ο Indicative for April 2026:
1.5y bullet : Euribor 3M (2. 15%) + 37.8 bps
3y bullet : Euribor 3M (2. 15%) + 37.6 bps
6y bullet : Euribor 3M (2. 15%) + 48.9 bps
Interest Payment Semi -annual (11 March, 11 September)
Non -Utilisation Fee Concessional rate on undrawn balance (expiry of a waiver of the
non -utilisation fee in the original Facility)
Use of Proceeds Vaccines, equipment, up to 3% for operations
Security Pledged donations and accounts
06b African Vaccine Manufacturing Accelerator AVMA pdf
Board- 2026-Mtg- 02-Doc 06b 1
Report to the Board
1 -2 July 2026
Subject African Vaccine Manufacturing Accelerator (AVMA)
Agenda item 06b
Category Decision
Executive Summary
The African Vaccine Manufacturing Accelerator (AVMA) was approved by the Gavi
Board in December 2023 and launched in June 2024 as a ten- year, US$ 1 billion
pull- financing instrument to support commercially sustainable vaccine
manufacturing in Africa. Eight een months in, AVMA is delivering against its design:
the first milestone disbursement is envisaged in late 2026; eight African-
manufactured vaccine products are on a credible pathway to WHO prequalification;
thirteen technology transfers are underway acro ss six African countries; and
approximately US$ 3 billion in complementary ecosystem financing has been
mobilised since launch. AVMA attracted pledges of approximately US$ 189 million
above the Board-approved US$ 1 billion ceiling, which require a Board decision
before they can be deployed. Following guidance from the October 2025
Programme and Policy Committee (PPC) and the December 2025 Board, the
Secretariat developed proposals for programming the additional pledges in
consultation with AVMA investors, m anufacturers, partners, and African Union
constituencies. The proposals were considered by the PPC at its meeting in May
2026. The PPC recommended to the Board the establishment of two new windows
within AVMA — a Vaccine Buy -Down Window covering Gavi’s costs for AVMA-
e ligible vaccines (not including country co- financing), and a one- off Ecosystem
Support Window. The PPC also recommended an accelerated, narrow Course
Correction to AVMA’s key terms in advance of the planned, regular 2027 Course
Correction, to take account of the changed operating context since AVMA’s launch
in 2024. Separately, following the World Health Organization’s declaration on
17 May 2026 of a Public Health Emergency of International Concern (PHEIC) in
respect of the outbreak of Ebola, the CEO proposes immediately amending AVMA’s
key terms to allow Afr ican-manufactured vaccines approved under WHO
Emergency Use Listing (EUL) to be designated a Priority Vaccine under AVMA .
Action Requested of the Board
The Gavi Alliance Programme and Policy Committee (PPC) recommends to the
Gavi Alliance Board that it:
a) Approve the programming of the additional US$ 189 million in African Vaccine
Manufacturing Accelerator (AVMA) pledges above the Board- approved
US$ 1 billion ceiling in support of a time- limited addendum to the AVMA key
terms as set out in Annex A to Doc 06b, known as “AVMA+”;
06b Annex A AVMA and Addendum to Key Terms pdf
Board-2026-Mtg -02-Doc 06b-Annex A 1
Report to the Board
1-2 July 2026
Annex A: AVMA+ Addendum to Key Terms
This Annex provides an updated overview of key terms of the AVMA approved by the
Gavi Board Board- 2024-Mtg -02- Doc 11b- Annex A: AVMA Base Proposal, which
themselves were updated from Board- 2023-Mtg-04- Doc 10b - Annex A: AVMA Key
Terms.
2026 Proposed updates are shown in bold underline and are restricted to the
acceptance of EUL for vaccines against Bundibugyo virus disease (BVD), and
components to be considered by the July 2026 Board, proposals known as AVMA+.
Core Terms
Design
element
Details
Size Funding requirement of US$ 750-
1,000 million – with the upper end of the
range set to accommodate an ambitious outcome for African products in
terms of number of incentivised manufacturers and their commercial
volumes
Scope All Gavi Alliance supported vaccines (with differences in payments, see
“Incentives”), fill & finish
-only (i.e. drug product), and “end -to - end” drug
substance + drug product.
Duration To be
launched in June 2024 with a proposed duration of 10 years (payments can continue for a period beyond the 10- year mark, depending
on tender lengths)
Eligibility
Vaccine Type: Qualifying Vaccine that is WHO Prequalified (or, in the case of
a vaccine for Bundibugyo virus disease (BVD) , in receipt of WHO
Emergency Use Listing).
Manufacturing Type:
i) The Qualifying Vaccine is Fully Manufactured on the African
continent;
or
ii) Fill & Finish of the Qualifying Vaccine is carried out in a
manufacturing facility on the African continent that is Controlled
by the holder of the WHO Pre- Qualification of the Qualifying
Vaccine.
Procurement
pathway Via successful Gavi
-UNICEF tenders and fulfil all other eligibility criteria
A potential AU pooled procurement mechanism may be accommodated in
the future, subject to determination in line with AVMA’s governance
arrangements)
06b Annex B Allocation methodology and partner ceilings pdf
Board-2026-Mtg -02-Doc 06b-Annex B 1
Report to the Board
1-2 July 2026
Annex B: Ecosystem Support — Allocation methodology and partner ceilings
This annex presents the allocation outcomes, following the Independent Review
Committee's (IRC) review (see Appendix 1 ) of the joint partner proposal for the AVMA+
Ecosystem Support Window (see Appendix 2). It presents IRC endorsed methodology
the Secretariat has applied to translate IRC ratings into indicative per -partner ceilings,
and the resulting funded and not -funded workstreams.
1. The IRC's assessment
The joint proposal was reviewed by the IRC against eight assessment criteria: Risk
Framework mapping, Theory of Change, Results Framework and Measurability,
Additionality and Non -Duplication, Mode of Delivery and Readiness, Institutional
Capacity, Budget Q uality and Realism, and Value for Money. The IRC produced an
overall alignment rating (High, Medium, or Low) for each partner on each AVMA risk
that partner addressed.
The matrices below set out the IRC's per -cell ratings. Figure 1a covers the three high-
priority risks where the substantive funding decisions are concentrated. Figure 1b
covers the medium - and lower -priority risks. The table in Section 4 provides a key to
the Risk codes, which are elaborated further in Appendix 3: AVMA Risk Management
Framework .
Figure 1a. IRC alignment ratings — HIGH-priority risks (A.3, D.7, B.2).
07 Annex A Financial Forecast additional details as of 18 June pdf
Board-2026-Mtg -02-Doc 07-Annex A 1
Report to the Gavi Board
1-2 July 2026
Annex A: Financial Forecast Additional Information
1. Gavi 6.0 prior forecast (v23) restatement
1.1. The v23 ( December 2025 Board) expenditure forecast has been restated to
present Catalytic Phase and Fragile & Humanitarian approach costs allocated
against the relevant vaccine and cash programmes (where previously these
were reported as single- line envelopes, under cash programmes).
Figure 1: restatement of prior forecast
2. Gavi 6.0 v23.2 financial forecast: Consolidated financial view
2.1. The ‘Gavi 6.0’ forecast has been prepared in line with the Board approved
strategy and resources / expenditure envelopes of US$ 10.2 billion (including
AVMA+, subject to Board approval) . In addition, the Secretariat has prepared
updated projections of expenditures for the 2026- 2030 period for other
programmes, including the African Vaccine Manufacturing Accelerator (AVMA),
the Pandemic Prevention Preparedness and Response (PPPR) Coalition, the
First Response Fund (FRF) and legacy COVAX Advance Market Commit ment
07 Annex A Financial Forecast additional details pdf
Board-2026-Mtg -02-Doc 07-Annex A 1
Report to the Gavi Board
1-2 July 2026
Annex A: Financial Forecast Additional Information
1. Gavi 6.0 prior forecast (v23) restatement
1.1. The v23 ( December 2025 Board) expenditure forecast has been restated to
present Catalytic Phase and Fragile & Humanitarian approach costs allocated
against the relevant vaccine and cash programmes (where previously these
were reported as single- line envelopes, under cash programmes).
Figure 1: restatement of prior forecast
2. Gavi 6.0 v23.2 financial forecast: Consolidated financial view
2.1. The ‘Gavi 6.0’ forecast has been prepared in line with the Board approved
strategy and resources / expenditure envelopes of US$ 10.2 billion (including
AVMA+, subject to Board approval) . In addition, the Secretariat has prepared
updated projections of expenditures for the 2026- 2030 period for other
programmes, including the African Vaccine Manufacturing Accelerator (AVMA),
the Pandemic Prevention Preparedness and Response (PPPR) Coalition, the
First Response Fund (FRF) and legacy COVAX Advance Market Commit ment
08 Annex A Gavi Alliance Risk Appetite Statement version 4 0 pdf
Gavi Alliance Risk
Appetite Statement
JULY 2026 VERSION 4.0Doc 08 - Annex A
Cover image credit: Gavi/2026
Document administration
Version number Approval processDate
1.0 Reviewed and recommended by: Gavi Programme & Policy Committee 10 November 2014
Approved by: Gavi Alliance Board 11 December 2014
2.0 Reviewed and recommended by: Gavi Audit & Finance Committee27 April 2017
Approved by: Gavi Alliance Board 15 June 2017
3.0 Reviewed and recommended by: Gavi Audit & Finance Committee7 June 2021
Approved by: Gavi Alliance Board 23 June 2021
3 .1 Reviewed and recommended by: Gavi Audit & Finance Committee17 October 2023
Approved by: Gavi Alliance Board 6–7 December 2023
4.0 Reviewed and recommended by: Gavi Audit & Finance Committee4 June 2026
Approved by: Gavi Alliance Board 1–2 July 2026
Effective from: 2 July 2026
Next review: As and when requested
02Doc 08 - Annex A
Appetite Statement
JULY 2026 VERSION 4.0Doc 08 - Annex A
Cover image credit: Gavi/2026
Document administration
Version number Approval processDate
1.0 Reviewed and recommended by: Gavi Programme & Policy Committee 10 November 2014
Approved by: Gavi Alliance Board 11 December 2014
2.0 Reviewed and recommended by: Gavi Audit & Finance Committee27 April 2017
Approved by: Gavi Alliance Board 15 June 2017
3.0 Reviewed and recommended by: Gavi Audit & Finance Committee7 June 2021
Approved by: Gavi Alliance Board 23 June 2021
3 .1 Reviewed and recommended by: Gavi Audit & Finance Committee17 October 2023
Approved by: Gavi Alliance Board 6–7 December 2023
4.0 Reviewed and recommended by: Gavi Audit & Finance Committee4 June 2026
Approved by: Gavi Alliance Board 1–2 July 2026
Effective from: 2 July 2026
Next review: As and when requested
02Doc 08 - Annex A
09 Annex A Risks and Mitigations pdf
Board-2026- Mtg-02-Doc 09-Annex A
Report to the Board
1-2 July 2026
Annex A : Risk implication and mitigation including for countries and the Alliance
This annex outlines the risks and proposed mitigation measures associated with the
implementation of the Vaccine Budget Policy . The risks and mitigations are based on
Gavi Secretariat analysis and consultations with Alliance partners and countries.
Key risks and mitigation measures are outlined in the table below:
Risk Mitigation measures
Country Financial & Implementation Risks
Countries not making a formal decision
to discontinue existing programmes
but delaying co-financing payments
and entering into default for specific
programmes .
Country communication to underscore and explain the
implications of the Vaccine Budgets (VB) and
allocating additional funding if available .
Unpredictable or inaccurate demand
leading to underfunding or stock -outs .
VBs represent Gavi?s best understanding of country
demand. The methodology reflects the demand
forecast for programmes under guaranteed budgets,
which offers a good level of accuracy of the needs of
countries especially for ongoing programmes. The
budgets are less accurate for N ew Vaccine
I ntroductions (NVIs) and preventative campaigns,
however the aim is to ensure predictable funding for
countries . Where new funding needs arise they will be
considered through the annual review mechanism and
prioritised according to the prioritisation logic.
Increased burden on country domestic
resources (self-financing in addition to
co -financing) .
The cumulative impact of the Gavi 6.0 changes to
Gavi?s operating model ( Eligibility and Transition, and
Co -financing Policies , VBs, campaign co -financing) is
reflected in higher requirements for domestic resource
investments in immuni sation, where those resources
may not be available. The VB design has Initial Self -
Financing ( ISF) country
floors that ensure these
countries do not need to self - finance their existing
programmes. The design has also considered the
need for self-financing in Accel erated Transition ( AT)
and Preparatory Transition (PT ) countries and
minimised it in discretionary budget
allocations to
balance out the impact across PT and AT countries
whose VB is expected to not fully meet the costs of
ongoing programmes. The policy also introduces the
possibility for countries to self -finance portions of their
programmes and not t he complete programme with
the possibility of reinvesting in another programme,
while other innovative financing options are being
made available to countries through the Mu ltilateral
Development Bank ( MDB) multiplier.
09 Annex B Vaccine Budget Policy clean version pdf
Board-2026- Mtg-02-Doc 09-Annex B
Classified as Internal
Report to the Board
1 -2 July 2026
Gavi Alliance
Va ccine Budget Policy
Version 1.0
DOCUMENT ADMINISTRATION
VERSION
NUMBER APPROVAL PROCESS DATE
1.0
Prepared by: Ombline Richard,
Head, Policy
Reviewed by: Gavi P rogramme and
Policy Committee
Approved by: Gavi Alliance Board
13 May 2026
TBD
Effective from: 3 July 2026
Next review: As and when required
2
Board -2026- Mtg-02-Doc 09-Annex B
Classified as Internal
Gavi Alliance
Vaccine Budget Policy
1. Scope and purpose
1.1. This policy defines the rules for the allocation of funding through c ountry-specific
Vaccine Budget s.
• The Vaccine Budget s appl y to Gavi -eligible countries
1, as outlined in the Gavi
F unding Guidelines , for funding over one five -year strategic period.
• It applies to the procurement of Gavi -supported vaccines , devices and freight.
1.2. The policy does not apply to Gavi support for emergencies, outbreaks or
diagnostics .
1.3. This policy should be considered together with the Eligibility and Transition Policy,
Co -financing Policy and the Health Systems and Immunisation Strengthening
(HSIS) Policy .
1.4. The objectives of the policy are to:
• Maximise health impact and value for money ,
• Minimise risk of outbreaks ,
• Ensure equitable access to vaccines ,
• Improve financial and programmatic sustainability , and
• Protect market health.
1.5. The following principles guide the design and implementation of the Vaccine
Budget policy:
• Flexibility for countries: Ensure countries have flexibility and decision-
making autonomy to manage trade- offs within their allocated budget.
• Continuity of support : Minimise disruptions of existing vaccine programmes
already introduced by countries.
• Simplicity : Ensure predictability of funding for countries and operational
feasibility.
2. Definitions
• Vaccine Budget : Country -specific allocations provided to Gavi -eligible
countries for their vaccine procurement support over a five -year strategic
period, made up of two components , guaranteed and discretionary, and subject
to updates through review of allocations and the prioritisation process .
• Initial Self -F inancing (ISF) Floor: Vaccine Budget s for ISF countries include
enough support to ensure continuity of their existing vaccine programmes that
fall under the discretionary budget and to ensure malaria vaccine scale- up and
new malaria vaccine introductions in up to 70% of moderate - to high-
transmission areas.
1 Catalytic phase countries also receive funding from the total allocation for Vaccine Budgets per
the funding guidelines but are not subject to this policy.
09 Annex C Vaccine Budget Policy marked up version from PPC version pdf
Board -2026 -Mtg -02-Doc 09 -Annex C
Report to the Board
1 - 2 July 2026
Classified as Internal
Gavi Alliance
Va ccine Budget Policy
Version 1.0
DOCUMENT ADMINISTRATION
VERSION
NUMBER APPROVAL PROCESS DATE
1.0
Prepared by: Ombline Richard,
Head, Policy
Reviewed by: Gavi P rogramme and
Policy Committee
Approved by: Gavi Alliance Board
13 May 2026
TBD
Effective from: 3 July 2026
Next review: As and when required
2
Board -2026 -Mtg -02-Doc 09 -Annex C
Gavi Alliance
Vaccine Budget Policy
Classified as Internal
1. Scope and p urpose
1.1. This policy defines the rules for the allocation of funding through c ountry -specific
Vaccine Budget s.
• The Vaccine Budget s appl y to Gavi -eligible countries 1, as outlined in the Gavi
Funding Guidelines , for funding over one five -year strategic period.
• It applies to the procurement of Gavi -supported vaccines , devices and freight.
1.2. The policy does not apply to Gavi support for emergencies, outbreaks or
diagnostics .
1.3. This policy should be considered together with the Eligibility and Transition Policy ,
Co -financing Policy and the Health Systems and Immunisation Strengthening
(HSIS) Policy .
1.4. The objectives of the policy are to :
• Maximise health impact and value for money ,
• Minimise risk of outbreaks ,
• Ensure equitable access to vaccines ,
• Improve financial and programmatic sustainability , and
• Protect market health .
1.5. The following principles guide the design and implementation of the Vaccine
Budget policy:
• Flexibility for countries : Ensure countries have flexibility and decision -
making autonomy to manage trade -offs within their allocated budget.
• Continuity of support : Minimise disruptions of existing vaccine programmes
already introduced by countries.
• Simplicity : Ensure predictability of funding for countries and operational
feasibility.
2. Definitions
• Vaccine Budget : Country -specific allocations provided to Gavi -eligible
countries for their vaccine procurement support over a five -year strategic
period , made up of two components , guaranteed and discretionary, and subject
to updates through review of allocation s and the prioritisation process .
• Initial Self -Financing (ISF) Floor: Vaccine Budget s for ISF countries include
enough support to ensure continuity of their existing vaccine programmes that
fall under the discretionary budget and to ensure malaria vaccine scale -up and
new malaria vaccine introductions in up to 70% of moderate - to high -
transmission areas.
1 Catalytic phase countries also receive funding from the total allocation for Vaccine Budgets per
the funding guidelines but are not subject to this policy.